Compare predictions BIO vs INFU
Loading...
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a StrongSell and INFU is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 0 FA rating(s) are green whileINFU’s FA Score has 0 green FA rating(s).
- BIO’s FA Score: 0 green, 5 red.
- INFU’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 4 TA indicator(s) are bullish while INFU’s TA Score has 4 bullish TA indicator(s).
- BIO’s TA Score: 4 bullish, 6 bearish.
- INFU’s TA Score: 4 bullish, 2 bearish.
Price Growth
BIO (@Medical Specialties) experienced а -1.35% price change this week, while INFU (@Medical Specialties) price change was -0.98% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.43%. For the same industry, the average monthly price growth was -5.27%, and the average quarterly price growth was +16.21%.
Reported Earning Dates
BIO is expected to report earnings on Jul 25, 2024.
INFU is expected to report earnings on Aug 15, 2024.
Industries' Descriptions
@Medical Specialties (+0.43% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BIO | INFU | BIO / INFU | |
| Capitalization | 9.79B | 187M | 5,237% |
| EBITDA | -654.76M | 16.2M | -4,042% |
| Gain YTD | -14.541 | -22.960 | 63% |
| P/E Ratio | 3.64 | 195.13 | 2% |
| Revenue | 2.67B | 123M | 2,172% |
| Total Cash | 1.61B | 161K | 998,137% |
| Total Debt | 1.41B | 36.3M | 3,871% |
BIO | INFU | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 72 | |
SMR RATING 1..100 | 92 | 88 | |
PRICE GROWTH RATING 1..100 | 65 | 76 | |
P/E GROWTH RATING 1..100 | 83 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BIO's Valuation (78) in the Medical Specialties industry is in the same range as INFU (89). This means that BIO’s stock grew similarly to INFU’s over the last 12 months.
INFU's Profit vs Risk Rating (72) in the Medical Specialties industry is in the same range as BIO (100). This means that INFU’s stock grew similarly to BIO’s over the last 12 months.
INFU's SMR Rating (88) in the Medical Specialties industry is in the same range as BIO (92). This means that INFU’s stock grew similarly to BIO’s over the last 12 months.
BIO's Price Growth Rating (65) in the Medical Specialties industry is in the same range as INFU (76). This means that BIO’s stock grew similarly to INFU’s over the last 12 months.
BIO's P/E Growth Rating (83) in the Medical Specialties industry is in the same range as INFU (100). This means that BIO’s stock grew similarly to INFU’s over the last 12 months.
| BIO | INFU | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 78% | N/A |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 77% |
| Momentum ODDS (%) | 1 day ago 63% | 1 day ago 74% |
| MACD ODDS (%) | 1 day ago 64% | 1 day ago 70% |
| TrendWeek ODDS (%) | 1 day ago 60% | 1 day ago 75% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 77% |
| Advances ODDS (%) | 5 days ago 66% | N/A |
| Declines ODDS (%) | 3 days ago 58% | 3 days ago 73% |
| BollingerBands ODDS (%) | 1 day ago 75% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 59% | 1 day ago 70% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GGLL | 43.27 | 7.25 | +20.13% |
| Direxion Daily GOOGL Bull 2X Shares | |||
| AMOM | 36.93 | 0.42 | +1.16% |
| QRAFT AI-Enhanced US Large Cap Mmntm ETF | |||
| ITOT | 111.74 | 1.07 | +0.97% |
| iShares Core S&P Total US Stock Mkt ETF | |||
| PSCE | 56.33 | 0.37 | +0.66% |
| Invesco S&P SmallCap Energy ETF | |||
| AGGY | 42.16 | 0.06 | +0.14% |
| WisdomTree Yield Enhanced US Aggt Bd ETF | |||
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with BRKR. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then BRKR could also see price increases.
| Ticker / NAME | Correlation To BIO | 1D Price Change % | ||
|---|---|---|---|---|
| BIO | 100% | +0.12% | ||
| BRKR - BIO | 73% Closely correlated | +0.47% | ||
| RVTY - BIO | 71% Closely correlated | -0.57% | ||
| MTD - BIO | 56% Loosely correlated | +0.42% | ||
| TMO - BIO | 54% Loosely correlated | +0.33% | ||
| DHR - BIO | 52% Loosely correlated | +0.32% | ||
More | ||||
INFU and
Correlation & Price change
A.I.dvisor tells us that INFU and VCYT have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INFU and VCYT's prices will move in lockstep.
| Ticker / NAME | Correlation To INFU | 1D Price Change % | ||
|---|---|---|---|---|
| INFU | 100% | +6.70% | ||
| VCYT - INFU | 31% Poorly correlated | -0.87% | ||
| XRAY - INFU | 31% Poorly correlated | +0.72% | ||
| NVST - INFU | 30% Poorly correlated | +1.85% | ||
| SMTI - INFU | 29% Poorly correlated | +0.43% | ||
| BIO - INFU | 28% Poorly correlated | +0.12% | ||
More | ||||